-
Reply to: “irLI or Not irLI: That is the Question” J. Hepatol. (IF 25.7) Pub Date : 2024-03-13 Ciro Celsa, Giuseppe Cabibbo, David James Pinato
-
Expanding the Dialogue: A Closer Look at AIH Management and HCC Risk J. Hepatol. (IF 25.7) Pub Date : 2024-03-13 Dan Shan PhD
-
Letter to the Editor: The MAFLD and MASLD Conundrum: Is It Reinvention Of The Wheel? J. Hepatol. (IF 25.7) Pub Date : 2024-03-13 Mariana M. Ramírez-Mejía, Mohammed Eslam, Nahum Méndez-Sánchez
-
Prospective validation of the EASL management algorithm for acute kidney injury in cirrhosis J. Hepatol. (IF 25.7) Pub Date : 2024-03-11 Ann Thu Ma, Cristina Solé, Adrià Juanola, Laia Escudé, Laura Napoleone, Emma Avitabile, Martina Pérez-Guasch, Marta Carol, Enrico Pompili, Jordi Gratacós-Ginés, Anna Soria, Ana Belén Rubio, Marta Cervera, Maria José Moreta, Manuel Morales, Elsa Solà, Esteban Poch, Núria Fabrellas, Isabel Graupera, Elisa Pose, Pere Ginès
The management of acute kidney injury (AKI) in cirrhosis is challenging. The EASL guidelines proposed an algorithm, but this has never been validated. We aimed to prospectively evaluate this algorithm in clinical practice. Prospective cohort study of consecutive hospitalized patients with cirrhosis and AKI. EASL management algorithm includes identification/treatment of precipitating factors, 2-day
-
Validation of Baveno VII criteria and other non-invasive diagnostic algorithms for clinically significant portal hypertension in hepatitis delta J. Hepatol. (IF 25.7) Pub Date : 2024-03-11 Mathias JACHS M.D. Ph.D., Lisa SANDMANN M.D., Lukas HARTL M.D., Tammo TERGAST M.D., Michael SCHWARZ M.D., David Josef Maria BAUER M.D., Lorenz BALCAR M.D., Alena EHRENBAUER, Benedikt Silvester HOFER M.D., Markus CORNBERG M.D., Henrike LENZEN M.D., Katja DETERDING M.D., Michael TRAUNER M.D., Mattias MANDORFER M.D. Ph.D., Heiner WEDEMEYER M.D., Thomas REIBERGER M.D., Benjamin MAASOUMY M.D.
Non-invasive tests (NIT) for clinically significant portal hypertension (CSPH) in compensated advanced chronic liver disease (cACLD) lack validation in patients infected with hepatitis D virus (HDV). HDV-cACLD patients (LSM ≥10 kPa or histological METAVIR F3/F4 fibrosis) who underwent paired HVPG and NIT assessment at Medical University of Vienna or Hannover Medical School between 2013 and 2023 were
-
One-year transplant-free survival following hospital discharge after ICU Admission for ACLF in the Netherlands J. Hepatol. (IF 25.7) Pub Date : 2024-03-11 Jubi de Haan, Fabian Termorshuizen, Nicolette de Keizer, Diederik Gommers, Caroline den Hoed
Patients with acute decompensated (AD) liver cirrhosis or acute-on-chronic liver failure (ACLF) often require intensive care unit (ICU) admission for organ support. Existing research, mostly from specialized liver transplant centers, largely addresses short-term outcomes. Our aim was to evaluate in-hospital mortality and 1-year transplant-free survival after hospital discharge in the Netherlands. We
-
Efficacy of Stereotactic Ablative Radiotherapy in Patients with Oligometastatic Hepatocellular Carcinoma: A Phase II Study J. Hepatol. (IF 25.7) Pub Date : 2024-03-11 Seo Hee Choi, Byung min Lee, Jina Kim, Do Young Kim, Jinsil Seong
Stereotactic ablative radiotherapy (SABR) has demonstrated curative potential with survival benefits in patients with oligometastatic disease (OMD). However, limited evidence exists regarding its use in oligometastatic hepatocellular carcinoma (HCC). We aimed to prospectively investigate the efficacy and safety of SABR in patients with oligometastatic HCC. We enrolled patients with controlled primary
-
Pkd1l1-deficiency drives biliary atresia through ciliary dysfunction in biliary epithelial cells J. Hepatol. (IF 25.7) Pub Date : 2024-03-08 Yi Zou Lim, Min Zhu, Yunguan Wang, Tripti Sharma, Shannon Kelley, Estelle Oertling, Hao Zhu, Natasha Corbitt
Syndromic biliary atresia is a cholangiopathy characterized by fibro-obliterative changes in the extrahepatic bile duct (EHBD) and congenital malformations including laterality defects. The aetiology remains elusive and faithful animal models are lacking. Genetic syndromes provide important clues for underlying pathogenic mechanisms of disease. We investigated the role of the gene in syndromic biliary
-
Endothelial POFUT1 controls injury-induced liver fibrosis by repressing fibrinogen synthesis J. Hepatol. (IF 25.7) Pub Date : 2024-03-07 Shan He, Yuru Luo, Wangge Ma, Xiaoke Wang, Chengrong Yan, Wenyang Hao, Yuan Fang, Hongyu Su, Baochang Lai, Junhui Liu, Ying Xiong, Ting Bai, Xiaoyong Ren, Enqi Liu, Hua Han, Yue Wu, Zuyi Yuan, Yidong Wang
NOTCH signaling in liver sinusoidal endothelial cells (LSECs) regulates liver fibrosis, a pathological feature of chronic liver diseases. POFUT1 is an essential regulator of NOTCH signaling. Here, we investigated the role of LSECs-expressed POFUT1 in liver fibrosis. Endothelial-specific knockout mice were generated and subjected to experimental liver fibrosis by chronic carbon tetrachloride exposure
-
Van Gogh-like 2 is essential for the architectural patterning of the mammalian biliary tree. J. Hepatol. (IF 25.7) Pub Date : 2024-03-07 Michaela Raab, Ersi Christodoulou, Roopesh Krishnankutty, Andreea Gradinaru, Alexander Daniel Walker, Paula Olaizola, Nicholas Thomas Younger, Anabel Martinez Lyons, Edward Joseph Jarman, Konstantinos Gournopanos, Alexander von Kriegsheim, Scott Hamilton Waddell, Luke Boulter
In the developing liver, bipotent epithelial progenitor cells known as hepatoblasts undergo lineage segregation to form the two major epithelial cell types, hepatocytes that constitute the bulk of the liver parenchyma and biliary epithelial cells (cholangiocytes) which comprise the bile duct, a complex tubular network which is critical for normal liver function. Notch and TGFβ signalling promote the
-
Cutting edges in the HBV genome: How RNA splicing is involved in modulating virus ultrastructure to promote infection J. Hepatol. (IF 25.7) Pub Date : 2024-03-07 Stefan Seitz, Ralf Bartenschlager
-
Syngeneic Murine Models with Distinct Immune Microenvironments Represent Subsets of Human Intrahepatic Cholangiocarcinoma J. Hepatol. (IF 25.7) Pub Date : 2024-03-07 Jennifer L. Tomlinson, Binbin Li, Jingchun Yang, Emilien Loeuillard, Hannah E. Stumpf, Hendrien Kuipers, Ryan Watkins, Danielle M. Carlson, Jessica Willhite, Daniel R. O’Brien, Rondell P. Graham, Xin Chen, Rory L. Smoot, Haidong Dong, Gregory J. Gores, Sumera I. Ilyas
Cholangiocarcinoma (CCA) is a poorly immunogenic malignancy with limited survival. Syngeneic, immunocompetent mouse models of CCA are an essential tool to elucidate the tumor immune microenvironment (TIME), understand mechanisms of tumor immune evasion, and test novel immunotherapeutic strategies. The scope of this study was to develop and characterize immunocompetent CCA models with distinct genetic
-
The Synergism of Public Health Policies and Social Work May Reduce Mortality from Cancer, Liver Disease and Cardiovascular Disease J. Hepatol. (IF 25.7) Pub Date : 2024-03-06 Shijie GUO, Jingqiang ZENG
-
Reply to: “Familial clustering of MASLD: Rethinking strategies for population screening” J. Hepatol. (IF 25.7) Pub Date : 2024-03-06 Fahim Ebrahimi, Jonas F. Ludvigsson
-
Uric acid in pediatric MASLD definition: Is it time to implement diagnostic criteria? J. Hepatol. (IF 25.7) Pub Date : 2024-03-06 Anna Di Sessa, Stefano Guarino, Giuseppina Rosaria Umano, Emanuele Miraglia del Giudice, Pierluigi Marzuillo
-
Rare monogenic causes of steatotic liver disease masquerading as MASLD J. Hepatol. (IF 25.7) Pub Date : 2024-03-06 Martijn CGJ. Brouwers, David Cassiman
-
Autoimmune Hepatitis: Mycophenolate mofetil versus azathioprine as first line therapy J. Hepatol. (IF 25.7) Pub Date : 2024-03-06 Cem Şimşek MD, Staffan Wahlin MD, Cumali Efe MD
-
Multi-omics characterization of healthy and PSC human liver – what we knew and what we have learned J. Hepatol. (IF 25.7) Pub Date : 2024-02-28 Jenny Krause, Christoph Schramm
-
Using liver stiffness to predict and monitor the risk of decompensation and mortality in patients with alcohol-related liver disease J. Hepatol. (IF 25.7) Pub Date : 2024-02-28 Katrine Holtz Thorhauge, Georg Semmler, Stine Johansen, Katrine Prier Lindvig, Maria Kjærgaard, Johanne Kragh Hansen, Nikolaj Torp, Camilla Dalby Hansen, Peter Andersen, Benedikt Silvester Hofer, Wenyi Gu, Mads Israelsen, Mattias Mandorfer, Thomas Reiberger, Jonel Trebicka, Maja Thiele, Aleksander Krag
Liver stiffness measurements (LSM) are recommended for disease prognostication and monitoring. We evaluated if LSM, using transient elastography, and LSM changes predict decompensation and mortality in patients with alcohol-related liver disease (ALD). Observational cohort study of compensated patients at risk of ALD from Denmark and Austria. We evaluated the risk of decompensation and all-cause mortality
-
Multidrug-resistant bacterial infections after liver transplantation: prevalence, impact, and risk factors J. Hepatol. (IF 25.7) Pub Date : 2024-02-28 Rosa Martin-Mateos, Laura Martínez-Arenas, Ángela Carvalho-Gomes, Laia Aceituno, Valle Cadahía, María Magdalena Salcedo, Ana Arias, Sara Lorente Pérez, Aitor Odriozola, Javier Zamora, Marino Blanes, Óscar Len, Laura Benítez, Isabel Campos-Varela, María Luisa González Diéguez, Diego Rojo Lázaro, Jesús Fortún, Antonio Cuadrado, Natalia Marcos Carrasco, Manuel Rodríguez-Perálvarez, Carmen Navascues, Emilio
Multidrug-resistant (MDR) bacterial infections are an increasing healthcare problem worldwide. This study analyzes the incidence, burden, and risk factors associated with MDR infections after liver transplantation (LT). This retrospective, multicenter cohort study included adult patients who underwent LT between January 2017 and January 2020. Risk factors related to pre-LT disease, surgical procedure
-
Single cell landscape of functionally cured chronic hepatitis B patients reveals activation of innate and altered CD4-CTL-driven adaptive immunity J. Hepatol. (IF 25.7) Pub Date : 2024-02-28 Balakrishnan Chakrapani Narmada, Atefeh Khakpoor, Niranjan Shirgaonkar, Sriram Narayanan, Pauline Poh Kim Aw, Malay Singh, Kok Haur Ong, Collins Oduor Owino, Jane Wei Ting Ng, Hui Chuing Yew, Nu Soibah Binte Mohamed Nasir, Veonice Bijin Au, Reina Sng, Nivashini Kaliaperumal, Htet Htet Toe Wai Khine, Francesca Casuscelli di Tocco, Otsuka Masayuki, Shamita Naikar, Hui Xin Ng, Su Li Chia, Cindy Xin Yi
Hepatitis B surface antigen (HBsAg) loss or functional cure (FC), is considered the desirable therapeutic outcome for chronic hepatitis B (CHB) patients. However, the immune-pathological biomarkers and underlying mechanisms remain unclear. In this study we comprehensively interrogate disease-associated cell states (DACS) identified within intra-hepatic tissue and matched PBMCs from either CHB or FC
-
PTEN Deficiency Induces an Extrahepatic Cholangitis-Cholangiocarcinoma Continuum via Aurora kinase A in Mice J. Hepatol. (IF 25.7) Pub Date : 2024-02-28 Yan Yang, Jiale Wang, Jianhua Wan, Qianqian Cheng, Zenong Cheng, Xueli Zhou, Oliver Wang, Kelvin Shi, Lingxiang Wang, Bin Wang, Xiaohui Zhu, Jiaxiang Chen, Dongfeng Feng, Yang Liu, Yasmin Jahan-mihan, Ashley N. Haddock, Brandy H. Edenfield, Guang Peng, Jessica D. Hohenstein, Chantal E. McCabe, Daniel R. O'Brien, Chen Wang, Sumera I. Ilyas, Liuyan Jiang, Michael S. Torbenson, Huamin Wang, Raouf E. Nakhleh
The PTEN-AKT pathway is frequently altered in extrahepatic cholangiocarcinoma (eCCA). We aim to evaluate the role of PTEN in the pathogenesis of eCCA and find novel therapies for this disease. The gene in the biliary epithelial cells were genetically deleted using the Cre-loxp system. The pathologies were evaluated both macroscopically and histologically. The characteristics were further analyzed by
-
Reply to: Population-based screening works: Effect of integrating screening for hepatitis B and C into the general health check-up in Germany J. Hepatol. (IF 25.7) Pub Date : 2024-02-23 R. Biallas, R. Zimmermann, S. Dudareva
-
Potential augmentation of terlipressin antidiuretic effects by gabapentinoids J. Hepatol. (IF 25.7) Pub Date : 2024-02-23 Penelope N. Markham, Jasmohan S. Bajaj, Paul J. Thuluvath, David Koch, Joseph Palumbo
-
Changing from NAFLD to MASLD: The implications for health-related quality of life data J. Hepatol. (IF 25.7) Pub Date : 2024-02-23 Ryuki Hashida, Dan Nakano, Machiko Kawaguchi, Zobair M. Younossi, Takumi Kawaguchi
-
“Autoimmune Hepatitis: Azathioprine or Mycophenolate Mofetil for inducing remission?” J. Hepatol. (IF 25.7) Pub Date : 2024-02-23 Avinash Tiwari, Duncan Khanikar, Santosh Govind Rathod
-
CRKL dictates anti-PD-1 resistance by mediating tumor-associated neutrophil infiltration in hepatocellular carcinoma J. Hepatol. (IF 25.7) Pub Date : 2024-02-23 Peiyi Xie, Mincheng Yu, Bo Zhang, Qiang Yu, Yufei Zhao, Mengyuan Wu, Lei Jin, Jiuliang Yan, Binghai Zhou, Shuang Liu, Xiaoqiang Li, Chenhao Zhou, Xiaodong Zhu, Cheng Huang, Yongfeng Xu, Yongsheng Xiao, Jian Zhou, Jia Fan, Mien-Chie Hung, Qinghai Ye, Lei Guo, Hui Li
Immune checkpoint inhibitors (ICIs) resistance limits immunotherapy success in hepatocellular carcinoma (HCC). However, the mechanisms underlying immunotherapy resistance remain elusive. We aimed to identify the role of CT10 regulator of kinase-like (CRKL) in HCC against anti-PD-1 therapy. Gene expression in HCC specimens from 10 patients accepted anti-PD-1 therapy was identified by RNA-sequencing
-
An in-depth exploration of difference and similarity between NAFLD and MASLD J. Hepatol. (IF 25.7) Pub Date : 2024-02-23 Yubo Liu, Liao Tan
-
Should MMF treatment be the first-line therapy in autoimmune hepatitis? J. Hepatol. (IF 25.7) Pub Date : 2024-02-23 Laurent Alric
-
Let’s unite Hepatology! Become an EASL member today and discover your benefits J. Hepatol. (IF 25.7) Pub Date : 2024-02-15
-
-
-
-
Use of stem cell-derived hepatocytes to model liver disease J. Hepatol. (IF 25.7) Pub Date : 2024-02-15 Josef Blaszkiewicz, Stephen A. Duncan
-
Jaundice with severe leucocytosis J. Hepatol. (IF 25.7) Pub Date : 2024-02-15 Sarah Haxhe, Pamela Baldin, Pierre Trefois, Violaine Havelange, Nicolas Lanthier
-
-
-
-
Exploring the impact of the PNPLA3 I148M variant on primary human hepatic stellate cells using 3D extracellular matrix models J. Hepatol. (IF 25.7) Pub Date : 2024-02-15 Elisabetta Caon, Maria Martins, Harry Hodgetts, Lieke Blanken, Maria Giovanna Vilia, Ana Levi, Kessarin Thanapirom, Walid Al-Akkad, Jeries Abu-Hanna, Guido Baselli, Andrew R. Hall, Tu Vinh Luong, Jan-Willem Taanman, Michele Vacca, Luca Valenti, Stefano Romeo, Giuseppe Mazza, Massimo Pinzani, Krista Rombouts
The rs738409 C>G (encoding for I148M) variant is a risk locus for the fibrogenic progression of chronic liver diseases, a process driven by hepatic stellate cells (HSCs). We investigated how the I148M variant affects HSCs biology using transcriptomic data and validated findings in 3D-culture models. RNA sequencing was performed on 2D-cultured primary human HSCs and liver biopsies of obese individuals
-
Submit your late-breaker abstract for the EASL Congress 2024 between 27 March - 10 April J. Hepatol. (IF 25.7) Pub Date : 2024-02-15
-
From the Editor’s Desk... J. Hepatol. (IF 25.7) Pub Date : 2024-02-15 Patrizia Burra, Frank Tacke, Vlad Ratziu, Stefan Zeuzem, Bruno Sangro, Paolo Angeli
-
Reply to: “Hepatic encephalopathy and survival after transjugular intra-hepatic portosystemic shunt: Do spontaneous portosystemic shunts matter?” J. Hepatol. (IF 25.7) Pub Date : 2024-02-15 Silvia Nardelli, Filippo Schepis, Francesco Vizzutti
-
Tailoring allocation policies and improving access to pediatric liver transplantation in Italy: outframing and concluding J. Hepatol. (IF 25.7) Pub Date : 2024-02-13 Jean de Ville de Goyet
-
From the experimental to the clinical: deepening the understanding of mycophenolate mofetil combined with prednisolone therapy J. Hepatol. (IF 25.7) Pub Date : 2024-02-11 Yixuan Xu, Xiaofei Yu, Yongmei Guo
-
Reply to: ‘A risk prediction model for hepatocellular carcinoma after hepatitis B surface antigen seroclearance: Need a closer look!’ J. Hepatol. (IF 25.7) Pub Date : 2024-02-10 Hyun Yang, Jeong Won Jang
-
Dual Positivity for AFP-L3 and DCP Identifies Patients at Exceptionally High Risk for Post-LT HCC Recurrence J. Hepatol. (IF 25.7) Pub Date : 2024-02-10 Joshua S. Norman, Neil Mehta
-
Researchers call for more flexible editorial conduct rather than abruptly adopting only the new MASLD nomenclature J. Hepatol. (IF 25.7) Pub Date : 2024-02-09 Amedeo Lonardo, Fernando Bril, Stephen H. Caldwell, Mohammed Eslam, Jian-Gao Fan, Robert G. Gish, Henning Gronbaek, Madhusudana Girija Sanal, Norbert Stefan, Ayako Suzuki, Giovanni Targher, Herbert Tilg, Ming-Lung Yu, Ming-Hua Zheng, Jacob George
-
Chimeric antigen receptor-modified macrophages ameliorate liver fibrosis in preclinical models J. Hepatol. (IF 25.7) Pub Date : 2024-02-08 Hanren Dai, Cheng Zhu, Qian Huai, Wentao Xu, Jiejie Zhu, Xu Zhang, Xianzheng Zhang, Beicheng Sun, Honghai Xu, Minghua Zheng, Xiaolei Li, Hua Wang
Treatments directly targeting fibrosis remain limited. Given the unique intrinsic features of macrophages and their capacity to engraft in the liver, we genetically engineered bone marrow-derived macrophages with a chimeric antigen receptor (CAR) to direct their phagocytic activity against hepatic stellate cells (HSCs) in multiple mouse models. This study aimed to demonstrate the therapeutic efficacy
-
Sex-determining region Y gene promotes liver fibrosis and accounts for sexual dimorphism in its pathophysiology J. Hepatol. (IF 25.7) Pub Date : 2024-02-08 Xiao-Ning Wu, Meng-Zhou Wang, Nan Zhang, Wei Zhang, Jian Dong, Meng-Yun Ke, Jun-Xi Xiang, Feng Ma, Feng Xue, Jing-Jing Hou, Zhi-Jie Ma, Fu-Min Wang, Xue-Min Liu, Rongqian Wu, Timothy M. Pawlik, Kai Ye, Jun Yu, Xu-Feng Zhang, Yi Lv
Men are more prone to develop and die from liver fibrosis than women. In this study, we aim to investigate how sex-determining region Y gene (SRY) in hepatocytes promotes liver fibrosis. Hepatocyte-specific knock-in (KI), knockout (KO), and KI with platelet-derived growth factor receptor α () KO mice were generated. Liver fibrosis was induced in mice by bile duct ligation for 2 weeks or carbon tetrachloride
-
To the editor: Reply to the letter by Liu et al. entitled “Patients with Hepatocellular carcinoma and portal vein tumour thrombosis after successful downstaging may be candidates for liver transplantation: A meta-analysis” J. Hepatol. (IF 25.7) Pub Date : 2024-02-08 Arvinder Soin, Mickael Lesurtel, Pierre A. Clavien
-
Identifying the pivotal role of non-acute decompensation as a precursor to acute decompensation in cirrhosis J. Hepatol. (IF 25.7) Pub Date : 2024-02-08 Chien-Hao Huang, Ming-Hung Tsai, Chun-Yen Lin
-
One - or more - blind spot(s) unveiled in the new definition of decompensated cirrhosis J. Hepatol. (IF 25.7) Pub Date : 2024-02-08 Florent Artru, Thomas Reiberger
-
Blocking viral entry with bulevirtide reduces the number of HDV-infected hepatocytes in human liver biopsies J. Hepatol. (IF 25.7) Pub Date : 2024-02-08 Lena Allweiss, Annika Volmari, Vithika Suri, Jeffrey J. Wallin, John F. Flaherty, Dmitry Manuilov, Bryan Downie, Marc Lütgehetmann, Jan-Hendrik Bockmann, Stephan Urban, Heiner Wedemeyer, Maura Dandri
Bulevirtide (BLV) is a first-in-class entry inhibitor and the only approved treatment for patients chronically infected with HDV in Europe. We aimed to investigate the efficacy of BLV treatment in paired liver biopsies obtained at baseline and after 24 or 48 weeks of treatment. We performed a combined analysis of 126 paired liver biopsies derived from three clinical trials. In the phase II clinical
-
Therapeutic vaccine-induced plasma cell differentiation is defective in the presence of persistently high HBsAg levels J. Hepatol. (IF 25.7) Pub Date : 2024-02-07 Ruoyao Qi, Rao Fu, Xing Lei, Jinhang He, Yao Jiang, Liang Zhang, Yangtao Wu, Siling Wang, Xueran Guo, Feng Chen, Meifeng Nie, Man Yang, Yiyi Chen, Jing Zeng, Jingjing Xu, Hualong Xiong, Mujin Fang, Yuqiong Que, Youliang Yao, Yingbin Wang, Jiali Cao, Huiming Ye, Yali Zhang, Zizheng Zheng, Tong Cheng, Jun Zhang, Xu Lin, Quan Yuan, Tianying Zhang, Ningshao Xia
Mechanisms behind the impaired response of antigen-specific B cells to therapeutic vaccination in chronic hepatitis B virus (HBV) infection remain unclear. The development of vaccines or strategies to overcome this obstacle is vital for advancing the management of chronic hepatitis B. A mouse model, denominated as E6F6-B, was engineered to feature a knock-in of a B-cell receptor (BCR) that specifically
-
Increased Siglec-9/Siglec-9L interactions on NK cells predict poor HCC prognosis and present a targetable checkpoint for immunotherapy J. Hepatol. (IF 25.7) Pub Date : 2024-02-07 Rong Xiao, Ye Tian, Jiwei Zhang, Na Li, Mei Qi, Ling Liu, Jianping Wang, Zhenyu Li, Jie Zhang, Fabao Zhao, Tixiao Wang, Siyu Tan, Chunyang Li, Zhuanchang Wu, Mingyan Yu, Xuemei Jiang, Peng Zhan, Lifen Gao, Bo Han, Xinyong Liu, Xiaohong Liang, Chunhong Ma
NK cells are enriched in liver and play critical roles in HCC. NK cell-based anti-HCC therapy is becoming attractive but still rare. Siglec-9 interacts with its ligand (Siglec-9L) and restrains NK cell functions, suggesting it is a potential therapeutic target. However, Siglec-9/Siglec-9L interaction in HCC has not been reported, and a relevant intervention strategy is lacking. Here, we aim to illustrate
-
Major HBV splice variant encoding a novel protein important for infection J. Hepatol. (IF 25.7) Pub Date : 2024-02-07 Chen-Yen Chung, Cheng-Pu Sun, Mi-Hua Tao, Hui-Lin Wu, Sheng-Han Wang, Shiou-Hwei Yeh, Qing-Bing Zheng, Quan Yuan, Ning-Shao Xia, Kenji Ogawa, Kenji Nakashima, Tetsuro Suzuki, Pei-Jer Chen
HBV expresses more than 10 spliced RNAs from the viral pregenomic RNA, but their functions remain elusive and controversial. To address the function of HBV spliced RNAs, we generated splicing-deficient HBV mutants and conducted experiments to assess the impact of these mutants on HBV infection. HepG2-NTCP cells, human hepatocyte chimeric FRG mice (hu-FRG mice), and serum from patients with chronic
-
Changes of hepatic myeloid cells in chronic viral hepatitis and after cure and their clinical significance J. Hepatol. (IF 25.7) Pub Date : 2024-02-07 Cheng Guo, Congyun Liu, Kai Liu
-
Primary hypocholesterolemia is associated with an increased risk of hepatic complications in the general population J. Hepatol. (IF 25.7) Pub Date : 2024-02-06 Matthieu Wargny, Thomas Goronflot, Antoine Rimbert, Jérôme Boursier, Sofiane Kab, Joseph Henny, Antoine Lainé, Christophe Leux, Sarra Smati, Samy Hadjadj, Cédric Le May, Marcel Goldberg, Marie Zins, Bertrand Cariou
Beyond cardiovascular disease protection, the health consequences of very low concentrations of low-density lipoprotein-cholesterol (LDL-C) remain a matter of debate. In primary hypobetalipoproteinemia (HBL), liver steatosis and cirrhosis have occasionally been reported. Here, we aimed to investigate the association between HBL and the risk of hepatic complications (cirrhosis complications and/or primary
-
Nuclear miR-204-3p mitigates metabolic dysfunction-associated steatotic liver disease in mice J. Hepatol. (IF 25.7) Pub Date : 2024-02-06 Zhaowei Zou, Xiu Liu, Jie Yu, Tao Ban, Ziyi Zhang, Peiqi Wang, Renli Huang, Fuxin Zheng, Yafei Chang, Wanli Peng, Yubo Tang, Xiaoqing Feng, Ziying Zhao, Xiaofei Lv, Shuai Huang, Jiawei Guo, Yonghua Tuo, Zhijun Zhou, Sijia Liang
-
The Evolving Role of Serial Non-Invasive Tests in Predicting HCC in MASLD J. Hepatol. (IF 25.7) Pub Date : 2024-02-01 George Cholankeril, Fasiha Kanwal
Abstract not available